Participated · Seed · Jul 2026

Elle MD is developing a non-hormonal, easily removable vaginal contraceptive ring intended as a new option for birth control. The company has assembled a team including founder Jennifer Johnston, MD and several named contributors and advisors. It secured C$1.1 million in an oversubscribed pre-seed financing round to advance its program. The immediate plan for the capital is to enable the company's First-in-Human clinical trial at The Ottawa Hospital. The fundraising included multiple institutional and regional investors and local funds. No revenue, user metrics, prior valuations, or earlier funding rounds were disclosed in the announcement.

Participated · Seed · Feb 2026

pHathom Technologies, founded in 2024, is a Canadian climate-tech company building a platform that captures biogenic CO₂ from coastal bioenergy and industrial plants and converts it into stable dissolved inorganic carbon that naturally occurs in seawater. The treated water is then returned under closely matched conditions, eliminating the need for pipelines, long-distance transport, or geological injection while operating within current industrial footprints. The process is engineered for high standards of scientific measurement and third-party verification, aiming to deliver durable and auditable carbon removal credits. pHathom is piloting its technology through the $16 million Bioenergy Carbon Capture and Marine Storage Project backed by Canada’s Ocean Supercluster. Market validation includes selection for Frontier’s advanced purchase of carbon-removal credits and recognition as Foresight’s 2025 Atlantic Canada Startup of the Year. Financially, the company has secured more than $12 million in committed capital, including a recently closed $4 million seed equity round. The fresh funds will accelerate pilot deployments, expand scientific monitoring, and support regulatory engagement for broader commercialization.

Led · Seed · Oct 2025

Voltai develops technology that captures and converts ocean energy into practical renewable power for ships and other maritime applications. By supplying clean power directly from the ocean environment, the company aims to cut both emissions and operating costs for maritime operators, thus reducing the sector’s dependence on fossil fuels. Its solutions target a significant pain point for shipping and offshore industries seeking to decarbonize. The technology is positioned as a lower-carbon, cost-efficient alternative to traditional fuel sources. Led by CEO Maja Maher, Voltai plans to use its newly raised capital to expand operations and advance product development efforts. The CAD$1.83 million pre-seed infusion marks the company’s first disclosed external financing and will fund continued R&D and initial market deployment activities.

Led · Seed · Sep 2025

Blue Charm builds patient engagement tools that recruit people with specific conditions and valid prescriptions to complete surveys during treatment, compensating participants and delivering medication-adherence insights to pharmaceutical partners. The company plans to enhance product development and expand services for pharma clients by developing advanced data analysis to better understand patient experiences and non-adherence. Blue Charm intends to grow its user base and corporate customer support capabilities and to build a team to attract and support those clients and participants. The company currently employs 14 full-time staff and seven contractors and expects to add 10 staff members by the end of 2026. Founded in 2020 and led by CEO Greg Patey, the business leverages the founder’s prior experience in life sciences and drug-sample distribution. The new funding is intended to support these product and team expansions.

Participated · Equity · Jun 2025

3DBioFibR develops scalable biopolymer fibers using a patented dry‑spinning platform that can process over six biopolymers. Its fibers report performance metrics two to three times the strength of natural tissue and are produced at over 3,600× the scale of conventional wet spinning and electrospinning, with improved uniformity and cost‑efficiency. The company has signed paid development agreements and partnerships across tissue engineering, medical devices, defense, cosmetics, and apparel, including several multinational corporations. The recently closed financing will fund ISO 13485 certification, construction of a clean room, and manufacturing scale‑up to meet rising global demand for medical‑grade and performance biomaterials. 3DBioFibR positions itself as a supplier for regulated clinical and therapeutic applications and plans to expand commercial and clinical partnerships. The company is based in Halifax, Nova Scotia. 3D BioFibR develops patented, fully automated collagen-fiber manufacturing technology to produce biofibres that mimic natural materials such as spider silk and collagen. The company is focused on producing recombinant human collagen for the medical research market and launched two products in June: μCollaFibR and CollaFibR, a three-dimensional cell-culture scaffold. To scale production the firm is collaborating with PlantForm Corporation and plans to use PlantForm’s vivoXPRESS plant-based biologics platform rather than mammalian-cell systems. A recent collaborative project funded by Next Generation Manufacturing Canada aims to improve collagen expression scale, increase fiber manufacturing capacity, and validate methods for incorporating recombinant collagen feedstock. 3D BioFibR was founded in 2020 by Sullivan and CSO John Frampton, a biomedical engineering professor at Dalhousie University, and operates with a 12-person team. Financially, the company previously raised $550,000 in 2020 and $700,000 of equity in 2021, and closed an equity and debt round worth $3.52 million in July of this year. 3D BioFibR develops and produces high-value collagen fibers at commercial scale using a proprietary, fully automated dry-spinning process. The company says its process is the only one that produces diameter-controlled collagen fibers at commercial scale and is at least 3,600x faster than competing manufacturing methods. Its collagen fibers are positioned for use in 3D cell culture and tissue engineering, recreating the natural appearance, structure, and function of collagen. 3D BioFibR plans to expand facilities to include a climate-controlled biomanufacturing cleanroom and a new wet lab and cell culture facility to bring its premium collagen fiber products to market. The company is backed by seed financing and receiving government support, including a repayable contribution and NRC IRAP advisory and R&D funding to support development of an automated collagen fiber manufacturing system. Management emphasizes accelerating capacity to meet growing demand from tissue engineers. 3D BioFibR produces naturally sourced, high-value biofibers including collagen (CollaFibR™) and spider silk for use in biomedical engineering, 3D tissue culture, tissue engineering, green textiles, defense, and aerospace. The company uses a proprietary dry-spinning manufacturing process that the team says is faster than current methods and preserves the natural properties of the proteins. Recent messaging emphasizes transition from a lab-based process to an automated production system to deliver consistent, high-quality products at commercial scale. Management plans to scale up and automate manufacturing to be ready for first market sales in the second half of 2022. The company is prioritizing engagement with industry to secure commercial partnerships, with an initial focus on tissue culture and tissue engineering applications. 3D BioFibR was incorporated in July 2020 and is operating from Halifax, Nova Scotia. 3D BioFibR is an advanced biofibre materials company based in Halifax, Nova Scotia, Canada. It manufactures naturally sourced, high-value biofibres including spider silk, collagen and chitosan. The company targets applications across biomedical engineering, green textiles, defense and aerospace. Leadership includes CEO Kevin Sullivan and Chief Scientific Officer Dr. John Frampton. 3D BioFibR plans to use new capital to develop and commercialize its tissue engineering and biomedical device products and to scale up manufacturing of its biofibre platform. The firm raised external funding to support those development and commercialization efforts.